Why Omnicell Stock Trounced the Market on Tuesday
Key Points
Analysts underestimated its ability to grow revenue and profitability in the first quarter.
Management also raised certain guidance items, including adjusted profitability.
- 10 stocks we like better than Omnicell ›
Omnicell (NASDAQ: OMCL) is off to a roaring start this year, at least as far as its quarterly performance is concerned. On Tuesday, it published its first earnings report of the year, and Mr. Market greeted this very positively. Investors couldn't get their hands on the healthcare tech stock fast enough, and they powered to a nearly 21% gain that day.
A solid quarter
Omnicell's revenue rose by almost 15% year-over-year to a shade under $310 million that quarter. That handily beat the consensus analyst estimate of barely over $304 million. Both product and service revenue grew during the period, with the former advancing a robust 20% to nearly $175 million, and the latter increasing 8% to $135 million.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Better, Omnicell managed to more than double its net income not under generally accepted accounting principles (GAAP). This ever-important line item rose to $25 million from the year-ago profit of $12 million ($0.55 per share). Collectively, the prognosticators tracking the company's stock were expecting $0.33 per share.
In its earnings release, Omnicell wrote that the better-than-anticipated growth "reflected strong execution across the business, supported by demand for Omnicell's connected device portfolio and solid performance across the company's core points of care solutions."
Bottom-line guidance lifted
Omnicell also proffered guidance for its current quarter and the entirety of 2026. For the latter period it's expecting revenue of just under $1.22 billion to almost $1.26 billion. The company increased its non-GAAP (adjusted) net income per share forecast to $1.80 to $2.00.
To me, Omnicell is operating very effectively in medical segments (hospitals and pharmacies) that will continue to benefit from the efficiencies its products and services offer. I'm not surprised that it posted better-than-expected numbers, and fully expect it to repeat this feat in the coming quarters.
Should you buy stock in Omnicell right now?
Before you buy stock in Omnicell, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Omnicell wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $492,752!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,327,935!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 28, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
